Social disparities and prostate cancer: mapping the gaps in our knowledge

被引:58
作者
Gilligan, T
机构
[1] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Dept Med Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA
关键词
cancer disparities; health disparities; prostate cancer; race; review article;
D O I
10.1007/s10552-004-1291-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To evaluate the current state of our knowledge regarding social disparities and prostate cancer and to map the domains where substantial knowledge has been acquired as well as those where little is known, with the purpose of identifying important areas for future research. A Medline research was conducted to identify published papers regarding social disparities in prostate cancer since 1990. The results of this review are presented in a social disparities and prostate cancer grid designed to highlight which domains of social disparities have been researched and which neglected. The major social disparity in prostate cancer concerns the extremely high prostate cancer incidence and mortality seen among black Americans. This is also the area where the most research has been performed. Low socioeconomic position is associated with poorer prostate cancer outcomes but not with higher prostate cancer incidence. It remains poorly defined to what extent racial/ethnic differences in prostate cancer result from differences in socioeconomic position (SEP). Understanding the causes of the high prostate cancer mortality seen among black men remains the major challenge in the area of social disparities and prostate cancer.
引用
收藏
页码:45 / 53
页数:9
相关论文
共 109 条
[1]   Do older men benefit from curative therapy of localized prostate cancer? [J].
Alibhai, SMH ;
Naglie, G ;
Nam, R ;
Trachtenberg, J ;
Krohn, MD .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3318-3327
[2]  
ANDERSSON SO, 1995, CANCER EPIDEM BIOMAR, V4, P187
[3]  
[Anonymous], J UROL
[4]   Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer [J].
Bennett, CL ;
Ferreira, MR ;
Davis, TC ;
Kaplan, J ;
Weinberger, M ;
Kuzel, T ;
Seday, MA ;
Sartor, O .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) :3101-3104
[5]  
Blumenfeld A J, 2000, Can J Urol, V7, P927
[6]   Prostate cancer: Demographic and behavioral correlates of stage at diagnosis among blacks and whites in North Carolina [J].
Conlisk, EA ;
Lengerich, EJ ;
Demark-Wahnefried, W ;
Schildkraut, JM ;
Aldrich, TE .
UROLOGY, 1999, 53 (06) :1194-1199
[7]   Factors that determine the treatment for local and regional prostate cancer [J].
Desch, CE ;
Penberthy, L ;
Newschaffer, CJ ;
Hillner, BE ;
Whittemore, M ;
McClish, D ;
Smith, TJ ;
Retchin, SM .
MEDICAL CARE, 1996, 34 (02) :152-162
[8]   Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial [J].
Duffield-Lillico, AJ ;
Dalkin, BL ;
Reid, ME ;
Turnbull, BW ;
Slate, EH ;
Jacobs, ET ;
Marshall, JR ;
Clark, LC .
BJU INTERNATIONAL, 2003, 91 (07) :608-612
[9]  
Eapen L, 1998, Chronic Dis Can, V19, P84
[10]  
Eton DT, 2001, CANCER, V92, P1451, DOI 10.1002/1097-0142(20010915)92:6<1451::AID-CNCR1469>3.0.CO